Aug 12, 2020
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
Aug 12, 2020
New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Aug 12, 2020
Chemotherapy-induced Nausea & Vomiting Drugs Market, 2024 - Focus on Serotonin & NK1 Receptor Antagonists and Other Therapies
Aug 11, 2020
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Jun 22, 2020
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Jun 22, 2020
ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA
Jun 18, 2020
Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti-PD-1/L1 Therapy
Jun 15, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
Jun 15, 2020
Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
Jun 12, 2020
EHA25Virtual: A New Paradigm in Relapsed Refractory Hodgkin Lymphoma
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 09, 2020
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
Jun 08, 2020
Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer
Jun 04, 2020
Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
May 31, 2020
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma
May 31, 2020
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
May 29, 2020
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint(TM)
May 29, 2020
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 29, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO